glp 1 agonist bone density New Research on GLP-1s & Health 🦴 ​A new large-scale study has raised questions about the long-term effects of GLP-1 receptor agonists (like Ozempic and Wegovy). While these medications are revolutionary Do glucagon-like peptide‑1 (GLP‑1) receptor

Our network meta-analysis has certain limitations

However, in subjects with or without pre-existing HF symptoms, linagliptin and sitagliptin had a neutral effect

Each has a different dose and some also include other mechanisms

Cho SW, Sontam T, Chen A, Limmer EE, Tolkachjov SN

Long-term conclusions rely on extrapolation Marie Spreckley, obesity researcher and public health nutritionist at the University of Cambridge in England, who was not involved in the study, cautioned that the papers long-term conclusions rely on modeled projections, rather than observed data, as the follow-up period for stopping treatment with newer medicines is limited to about 12 months

By activating GLP-1 receptors in multiple areas particularly the hypothalamus and vagus nerve this therapy helps reduce appetite, improve glycaemic control, and support healthier eating behaviours